Raymond James on Inflarx NV (IFRX): 'analyses of the unblinded Phase 3 dataset for vilobelimab...suggests evidence of a positive trend'
Tweet Send to a Friend
Raymond James analyst Ryan Deschner reiterated an Outperform rating and $9.00 price target on Inflarx NV (NASDAQ: IFRX).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
